Skip to content

Presbyopia Update

👁️ Presbyopia News 🆕

👁 𝐀𝐥𝐜𝐨𝐧 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐂𝐥𝐚𝐫𝐞𝐨𝐧 𝐏𝐚𝐧𝐎𝐩𝐭𝐢𝐱 𝐏𝐫𝐨 𝐓𝐫𝐢𝐟𝐨𝐜𝐚𝐥 𝐈𝐎𝐋 𝐢𝐧 𝐭𝐡𝐞 𝐔.𝐒.
Alcon is redefining presbyopia correction with the U.S. launch of its Clareon PanOptix Pro Trifocal IOL—an advanced intraocular lens designed to deliver exceptional vision at near, intermediate, and far distances. Built to address the challenges of presbyopia, this lens helps patients regain seamless visual range and reduce dependence on glasses. Featuring ENLIGHTEN Optical Technology, it offers 94% light utilisation and reduced light scatter, enhancing contrast and clarity in all lighting conditions. Delivered via the Clareon AutonoMe preloaded system, it ensures precise and efficient implantation. U.S. commercial rollout begins in May 2025, with international availability to follow.

👁 𝐎𝐫𝐚𝐬𝐢𝐬 𝐋𝐚𝐮𝐧𝐜𝐡𝐞𝐬 𝐐𝐋𝐎𝐒𝐈™ 𝐄𝐲𝐞 𝐃𝐫𝐨𝐩𝐬 𝐟𝐨𝐫 𝐏𝐫𝐞𝐬𝐛𝐲𝐨𝐩𝐢𝐚 𝐢𝐧 𝐭𝐡𝐞 𝐔.𝐒.
Orasis Pharmaceuticals has launched QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% in the U.S. to treat presbyopia. These preservative-free eye drops improve near vision by using a pinhole effect to adjust pupil size, while maintaining clear distance vision. QLOSI works within 20 minutes and lasts 8-12 hours. It’s recommended to use one drop per eye, up to twice daily, and remove contact lenses before application.